Stock listing
Frankfurt:J8P Cinclus Pharma Holding AB Aktie
German listing (Frankfurt) of Cinclus Pharma Holding AB · home listing Stockholm:CINPHA
Follow Cinclus Pharma Holding AB into a list and get an email when it puts out news.
Share price · FWB:J8P
€0.969 EUR +0.002 (+0.2%)
Close on Nov 20, 2026
- Day range
- €0.969 – €0.969 EURNov 20, 2026
- Market cap
- €45.10M EURAt the close on Nov 20, 2026 · price × 46.54M shares outstanding
- Traded on an average day
- €9 EURMedian day 0 shares · 55 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:CINPHA · Home | 11.22 SEK | -0.12 (-1.1%) | 46,511 | 11.38 | 11.38 | 11.00 | 11.34 | Close on Nov 20, 2026 |
| Frankfurt:J8P | €0.969 EUR | +0.002 (+0.2%) | — | €0.969 | €0.969 | €0.969 | €0.967 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:J8P · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.026 | +0.010 | +1.0% | €1.026 | €1.026 | €1.026 | 0 | |
| €1.016 | +0.026 | +2.6% | €1.016 | €1.016 | €1.016 | 0 | |
| €0.990 | -0.055 | -5.3% | €0.990 | €0.990 | €0.990 | 0 | |
| €1.045 | +0.009 | +0.9% | €1.045 | €1.045 | €1.045 | 0 | |
| €1.036 | -0.024 | -2.3% | €1.036 | €1.036 | €1.036 | 0 | |
| €1.060 | +0.056 | +5.6% | €1.060 | €1.060 | €1.060 | 0 | |
| €1.004 | -0.030 | -2.9% | €1.004 | €1.004 | €1.004 | 0 | |
| €1.034 | +0.004 | +0.4% | €1.034 | €1.034 | €1.034 | 0 | |
| €1.030 | +0.021 | +2.1% | €1.030 | €1.030 | €1.030 | 0 | |
| €1.009 | -0.005 | -0.5% | €1.009 | €1.009 | €1.009 | 0 | |
| €1.014 | -0.045 | -4.2% | €1.014 | €1.014 | €1.014 | 0 | |
| €1.059 | -0.024 | -2.2% | €1.059 | €1.059 | €1.059 | 0 | |
| €1.083 | +0.018 | +1.7% | €1.083 | €1.083 | €1.083 | 0 | |
| €1.065 | -0.017 | -1.6% | €1.065 | €1.065 | €1.065 | 0 | |
| €1.082 | -0.044 | -3.9% | €1.082 | €1.082 | €1.082 | 0 | |
| €1.126 | +0.024 | +2.2% | €1.126 | €1.126 | €1.126 | 0 | |
| €1.102 | +0.022 | +2.0% | €1.102 | €1.102 | €1.102 | 0 | |
| €1.080 | +0.002 | +0.2% | €1.080 | €1.080 | €1.080 | 0 | |
| €1.078 | -0.049 | -4.3% | €1.078 | €1.078 | €1.078 | 0 | |
| €1.127 | -0.016 | -1.4% | €1.127 | €1.127 | €1.127 | 0 | |
| €1.143 | +0.008 | +0.7% | €1.143 | €1.143 | €1.143 | 0 | |
| €1.135 | -0.003 | -0.3% | €1.135 | €1.135 | €1.135 | 0 | |
| €1.138 | -0.004 | -0.4% | €1.138 | €1.138 | €1.138 | 0 | |
| €1.142 | +0.057 | +5.3% | €1.142 | €1.142 | €1.142 | 0 | |
| €1.085 | -0.026 | -2.3% | €1.085 | €1.085 | €1.085 | 0 | |
| €1.111 | +0.006 | +0.5% | €1.111 | €1.111 | €1.111 | 0 | |
| €1.105 | -0.016 | -1.4% | €1.105 | €1.105 | €1.105 | 0 | |
| €1.121 | +0.120 | +12.0% | €1.065 | €1.121 | €1.057 | 238 | |
| €1.001 | +0.007 | +0.7% | €1.001 | €1.001 | €1.001 | 0 | |
| €0.994 | +0.024 | +2.5% | €0.994 | €0.994 | €0.994 | 0 | |
| €0.970 | -0.063 | -6.1% | €0.970 | €0.970 | €0.970 | 0 | |
| €1.033 | +0.043 | +4.3% | €1.033 | €1.033 | €1.019 | 238 | |
| €0.990 | -0.010 | -1.0% | €0.990 | €0.990 | €0.990 | 0 | |
| €1.000 | +0.018 | +1.8% | €1.000 | €1.000 | €1.000 | 0 | |
| €0.982 | +0.011 | +1.1% | €0.982 | €0.982 | €0.982 | 0 | |
| €0.971 | -0.009 | -0.9% | €0.971 | €0.971 | €0.971 | 0 | |
| €0.980 | -0.029 | -2.9% | €0.980 | €0.980 | €0.980 | 0 | |
| €1.009 | +0.005 | +0.5% | €1.009 | €1.009 | €1.009 | 0 | |
| €1.004 | -0.032 | -3.1% | €1.004 | €1.004 | €1.004 | 0 | |
| €1.036 | -0.024 | -2.3% | €1.036 | €1.036 | €1.036 | 0 | |
| €1.060 | -0.011 | -1.0% | €1.060 | €1.060 | €1.060 | 0 | |
| €1.071 | -0.001 | -0.1% | €1.071 | €1.071 | €1.071 | 0 | |
| €1.072 | -0.002 | -0.2% | €1.072 | €1.072 | €1.072 | 0 | |
| €1.074 | -0.005 | -0.5% | €1.074 | €1.074 | €1.074 | 0 | |
| €1.079 | +0.006 | +0.6% | €1.079 | €1.079 | €1.079 | 0 | |
| €1.073 | +0.035 | +3.4% | €1.073 | €1.073 | €1.073 | 0 | |
| €1.038 | -0.121 | -10.4% | €1.038 | €1.038 | €1.038 | 0 | |
| €1.159 | -0.037 | -3.1% | €1.159 | €1.159 | €1.159 | 0 | |
| €1.196 | +0.002 | +0.2% | €1.196 | €1.196 | €1.196 | 0 | |
| €1.194 | -0.011 | -0.9% | €1.194 | €1.194 | €1.194 | 0 | |
| €1.205 | +0.016 | +1.3% | €1.205 | €1.205 | €1.205 | 0 | |
| €1.189 | +0.008 | +0.7% | €1.189 | €1.189 | €1.189 | 0 | |
| €1.181 | +0.051 | +4.5% | €1.181 | €1.181 | €1.181 | 0 | |
| €1.130 | 0.000 | 0.0% | €1.130 | €1.130 | €1.130 | 0 | |
| €1.130 | +0.005 | +0.4% | €1.130 | €1.130 | €1.130 | 0 | |
| €1.125 | +0.108 | +10.6% | €1.125 | €1.125 | €1.125 | 0 | |
| €1.017 | +0.021 | +2.1% | €1.017 | €1.017 | €1.017 | 0 |
- Ticker
- Frankfurt:J8P
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Mar 13, 2026
Cinclus Pharma Enters into EUR 28 Million Financing Agreement
Latest news
Cinclus Pharma Enters into EUR 28 Million Financing Agreement
Mar 13, 2026
Closed €1.58 (+2.8%) on Mar 13, 2026
Cinclus Pharma Holding AB on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Mar 13, 2026 · oldest 2026
- Decks
- 3 decks · latest Aug 20, 2025
Where Cinclus Pharma Holding AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:CINPHA · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A3EN5G | LS Exchange | Germany | EUR |
| gettex:J8P | gettex | Germany | EUR |
| Munich:J8P | Munich | Germany | EUR |
| Turquoise:CINPAS | Turquoise | United Kingdom | SEK |
| Frankfurt:J8P · This page | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3EN5G | Lang & Schwarz | Germany | EUR |
| Stuttgart:J8P | Stuttgart | Germany | EUR |
Valuation
EV/sales 3.8× against a median of 8.6×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 134.2M SEK
- P/E
- Loss
- EV/sales
- 3.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.6×
- Gross margin
- Not reported
- Operating margin
- −830.1%
- Net margin
- −765.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cinclus Pharma Holding AB · OMXSTO:CINPHA | US$51.13M | US$13.15M | n/a | 3.8× | n/a | 2.6× | −765.8% | 0.0× | n/a |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| iBio, Inc. · NASDAQ:IBIO | US$51.45M | −US$23.13M | n/a | −21.5× | n/a | 0.7× | n/a | 0.0× | 2.01 |
| Sirnaomics Ltd. · HKEX:2257 | US$51.13M | US$69.20M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Aldeyra Therapeutics, Inc. · NASDAQ:ALDX | US$50.70M | US$9.72M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 0.66 |
| Clene Inc. · NASDAQ:CLNN | US$50.69M | US$58.31M | n/a | 245× | n/a | n/a | n/a | n/a | 1.48 |
| Acrivon Therapeutics, Inc. · NASDAQ:ACRV | US$49.35M | −US$26.60M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.09 |
| Aptamer Sciences, Inc. · KRX:291650 | US$49.20M | US$34.45M | n/a | 8.6× | n/a | 1.6× | −215.8% | 0.0× | n/a |
| Median of the others | US$51.29M | US$22.09M | 33.0× | 8.6× | 0.8× | −118.3% | 0.0× | 0.76 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 45.00 SEK · Analysts' mean
- EPS, year to Dec 2026
- -6.03 · 2 analysts
- Revenue, year to Dec 2026
- 85.93M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Christer Ahlberg | Chief Executive Officer and President |
| Magnus Christensen | Chief Financial Officer |
| Henrik Vikström | IR |
| Jesper Wiklund | Chief Business Officer |
| Kajsa Larsson | Chief Medical Officer |
| Lennart Hansson | Chairman of the Board, Co-founder |
| Peter Wallich | Commercial Director |
Board
| Director | Role |
|---|---|
| Lennart Hansson | Chairman of the Board, Co-founder |
| Anders Lundström | Non-executive Director |
| David Armstrong | Non-executive Director |
| Fredrik Johansson | Non-executive Director |
| Helena Levander | Non-executive Director |
| Torbjörn Koivisto | Non-executive Director |
| Wenche Rolfsen | Non-executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q1 2025 | May 20, 2025 · Before open | +6.5% |
| Q4 2024 | Feb 20, 2025 · Before open | −8.1% |
| Quarter to Sep 30, 2024 | Nov 14, 2024 · Before open | −6.3% |
| Quarter to Jun 30, 2024 | Aug 29, 2024 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2025 Earnings Presentation | Earnings | 13 slides | Aug 20, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 29 slides | Nov 14, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 16 slides | Aug 29, 2024 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 57.5M | 4.58M | 5.96M | 10.6M |
| Research and development | 198.4M | 136.7M | 166.7M | 157.2M |
| Selling, general and administrative | 57.2M | 36.9M | 39.6M | 64.1M |
| Operating income | -199.6M | -169.6M | -201.0M | -210.7M |
| Depreciation and amortization | 2.38M | 1.34M | 1.25M | 1.11M |
| EBITDA | -197.2M | -168.3M | -199.7M | -209.6M |
| Interest expense | 13.9M | 28.1M | 17.2M | 76.0K |
| Income before tax | -183.7M | -167.3M | -214.6M | -231.0M |
| Net income | -184.0M | -168.0M | -215.1M | -249.1M |
| Earnings per share, basic | -3.95 | -4.54 | -8.20 | -5.35 |
| Earnings per share, diluted | -3.95 | -4.54 | -8.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 487.3M | 566.7M | 88.0M | 173.5M |
| Receivables | 16.1M | 0 | ||
| Current assets | 536.9M | 600.5M | 94.1M | 184.9M |
| Total assets | 546.6M | 601.0M | 94.4M | 185.8M |
| Accounts payable | 48.5M | 18.9M | 16.4M | 16.9M |
| Current liabilities | 136.8M | 45.5M | 164.4M | 46.1M |
| Total liabilities | 177.2M | 45.7M | 171.2M | 58.9M |
| Shareholders' equity | 369.4M | 555.3M | -76.8M | 126.9M |
| Shares outstanding | 46.5M | 46.5M | 46.5M | 46.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -74.6M | -178.4M | -209.2M | -192.1M |
| Capital spending | -1.13M | 0 | 0 | 0 |
| Free cash flow | -75.8M | -178.4M | -209.2M | -192.1M |
| Cash from investing | -1.43M | 0 | ||
| Cash from financing | -1.76M | 655.2M | 122.9M | |
| Change in cash | -77.8M | 476.8M | -86.3M | 34.1M |
Cap table
Built by 6ix from Cinclus Pharma Holding AB’s releases
- Common shares
- 46,537,789
- Fully diluted
- 46,537,789
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 46,537,789 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 46,537,789 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anders Lundström | Non-executive Director · Since at least Nov 5, 2026 |
| Christer Ahlberg | Chief Executive Officer and President · Since at least Mar 13, 2026 |
| David Armstrong | Non-executive Director · Since at least Nov 5, 2026 |
| Fredrik Johansson | Non-executive Director · Since at least Nov 5, 2026 |
| Helena Levander | Non-executive Director · Since at least Nov 5, 2026 |
| Henrik Vikström | IR · Since at least Mar 13, 2026 |
| Jesper Wiklund | Chief Business Officer · Since at least Nov 5, 2026 |
| Kajsa Larsson | Chief Medical Officer · Since at least Nov 5, 2026 |
| Lennart Hansson | Chairman of the Board, Co-founder · Since at least Nov 5, 2026 |
| Magnus Christensen | Chief Financial Officer · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Peter Wallich | Commercial Director · Since at least Nov 5, 2026 |
| Torbjörn Koivisto | Non-executive Director · Since at least Nov 5, 2026 |
| Wenche Rolfsen | Non-executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Cinclus Pharma Holding AB.